Nanthealth LLC (NYSE:NH) shares saw an uptick in trading volume on Thursday . 196,637 shares were traded during mid-day trading, an increase of 129% from the previous session’s volume of 85,927 shares.The stock last traded at $12.63 and had previously closed at $12.44.

A number of brokerages have recently issued reports on NH. First Analysis began coverage on Nanthealth in a research note on Monday, June 27th. They issued an “overweight” rating and a $18.00 price objective on the stock. FBR & Co reissued a “buy” rating on shares of Nanthealth in a research note on Wednesday, August 10th. Canaccord Genuity began coverage on Nanthealth in a research note on Monday, June 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Jefferies Group began coverage on Nanthealth in a research note on Monday, June 27th. They issued a “buy” rating on the stock. Finally, Cowen and Company began coverage on Nanthealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $19.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $18.00.

The firm has a 50-day moving average price of $11.57 and a 200-day moving average price of $12.39. The stock’s market cap is $1.54 billion.

Nanthealth (NYSE:NH) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.26. The firm had revenue of $31.50 million for the quarter, compared to analysts’ expectations of $23.55 million. The business’s revenue for the quarter was up 166.9% compared to the same quarter last year. On average, analysts anticipate that Nanthealth LLC will post ($0.59) earnings per share for the current year.

In other news, major shareholder Healthcare Solution Allscripts purchased 714,286 shares of the stock in a transaction on Tuesday, June 7th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $10,000,004.00. Following the completion of the transaction, the insider now directly owns 15,000,000 shares of the company’s stock, valued at approximately $210,000,000. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Patrick Soon-Shiong purchased 357,143 shares of the stock in a transaction on Tuesday, June 7th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $5,000,002.00. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.